We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.
- Authors
Chivot, Justine; Ferrand, Nathalie; Fert, Aude; Van Dreden, Patrick; Morichon, Romain; Sabbah, Michèle
- Abstract
Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapies that inhibit PARP proteins which are involved in a variety of cell functions. PARPi may act as modulators of angiogenesis; however, the relationship between PARPi and the vasculogenic mimicry (VM) in breast cancer remains unclear. To determine whether PARPi regulate the vascular channel formation, we assessed whether the treatment with olaparib, talazoparib and veliparib inhibits the vascular channel formation by breast cancer cell lines. Here, we found that PARPi act as potent inhibitors of the VM formation in triple negative breast cancer cells, independently of the BRCA status. Mechanistically, we find that PARPi trigger and inhibit the NF-κB signaling, leading to the inhibition of the VM. We further show that PARPi decrease the expression of the angiogenic factor PTX3. Moreover, PTX3 rescued the PARPi-inhibited VM inhibition. In conclusion, our results indicate that PARPi, by targeting the VM, may provide a new therapeutic approach for triple negative breast cancer.
- Subjects
VASCULOGENIC mimicry; TRIPLE-negative breast cancer; ADP-ribosylation; POLY(ADP-ribose) polymerase; CANCER cells; BREAST cancer; POLY ADP ribose
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 24, p16171
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms232416171